Table 3.
Strategy-immune checkpoint inhibitors and vaccine combination therapy.
| Intervention | Strategy | Date (last updated) | Status | Patient population | Phase | Study design | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|---|
| Ipilimumab + GVAX | CTLA-4 inhibitor, Whole cell vaccine | 21 October 2015 | Recruiting | Metastatic Pancreatic cancer | II | Arm1- Ipilimumab + GVAX Arm2- FOLFIRINOX. Endpoint – Efficacy study |
NCT01896869 |
| Nivolumab + GVAX + Cyclophosphamide | PD-1 inhibitor, Whole cell vaccine, Cytotoxic drugs | 1 December 2015 |
Open but not recruiting | Surgically resectable pancreatic cancer | I/II | Arm A- CY/ GVAX Arm B- CY/ GVAX + Nivolumab |
NCT02451982 |
| Nivolumab+ GVAX+ CRS-207 | PD-1 inhibitor, Whole cell vaccine, Listeria vaccine | 23 September 2015 | Recruiting | Metastatic pancreatic cancer | II | Arm 1 – CY/ GVAX/ CRS-207/ Nivolumab Arm 2- CY/ GVAX/ CRS-207 |
NCT02243371 |